BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Flu antiviral TG-1000 receives FDA approval in Taiwan

02 November 2020 | News

TaiGen's Investigation New Drug (IND) application accepted for influenza A and B treatment

TaiGen Biotechnology Company, Limited (TaiGen) in Taiwan has announced that U.S. Food and Drug Administration (FDA) has approved the Investigation New Drug (IND) application for TG-1000, a novel treatment for influenza A and B.

TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses. The first US patent for TG-1000 was successfully prosecuted and granted by the United States Patent and Trademark Office on Jan 14th, 2020.

TaiGen is ready to extend the clinical study of TG-1000 to the U.S. in the near future.

According to Global Data, the global market for influenza antivirals reached 2.34 billion USD in 2019 and is estimated to reach 5.03 billion USD by 2026 at a CAGR of 11.5%. Currently the market is comprised primarily of the neuraminidase inhibitor oseltamivir and the newly developed endonuclease inhibitor baloxavir. With the recent introduction of baloxavir into the market, institutional investment analysts expect the market share of endonuclease inhibitors to increase at the expense of neuraminidase inhibitors. TaiGen’s TG-1000 is poised to take full advantage of this development.